CHAPEL HILL, N.C., April 13, 2018 /PRNewswire/ -- It's hard to overemphasize the importance of scientific publications tothe pharmaceutical industry - it is the principal way that physicians and KOLs learn scientific/medical information about a company's existing and pipeline products.
But the publications process can get bogged down by gray areas such as authorship
This new research study reviews the standards, processes and rationale of critical authorship selection and retention decisions. Publications leaders can use this research to shape their publication policies to avoid uncertainties and delays. Specifically, this study provides insights on guidance on the removal of an author from the publication, when an author is leaving for a competitor/non-competitor, circumstances under which former employee is allowed to remain lead author, and specification of authorship rights in employment contract.
In the study, a majority of companies said they don't balance the ratio of internal to external authors since ICMJE criteria don't differentiate between them. The study also found that there is no agreement on who is the best arbiter for determining who will be invited to be an author, although some type of group (publication team or trial-steering committee) is used by 48%.
"Authorship Selection for Medical Publications at Pharmaceutical and Biotech Companies" will serve as a reference for medical publication leaders to shape their authorship transition guidelines.
Key topics in the 48-page study include:
For this study, Best Practices, LLC engaged 23 leaders from biopharmaceutical companies and a publication services consultancy in this benchmarking research. The study has two data segments: Large Companies and Small to Medium Companies.
To access the full report or to download a complimentary summary containing insights found in this report, click on the following link: http://www.best-in-class.com/rr1492.htm.
For related research, visit the Best Practices, LLC Web site at www.best-in-class.com/.
ABOUT BEST PRACTICES, LLCBest Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis.
View original content:http://www.prnewswire.com/news-releases/new-pharmaceutical-industry-report-sheds-light-on-authorship-selection-transitions-in-scientific-publications-process-300629809.html
SOURCE Best Practices, LLC
Subscribe to our Free Newsletters!
Fallot's tetralogy is a rare and complex birth defect of the heart. Babies born with this condition ...
Bubonic plague is an infectious disease caused by the bacteria Yersinia pestis present in rodents ...
Steroids are miracle drugs but have to be used with caution. Some steroids are illegal to use, ...View All